Specific changes of sulfatide levels in individuals with pre-clinical Alzheimer's disease: An early event in disease pathogenesis

Journal of Neurochemistry

Volumn 127, Issue 6, 2013, Pages 733-738

  Cheng, Hua ^a   Wang, Miao ^a   Li, Jian Liang ^a   Cairns, Nigel J ^b   Han, Xianlin ^a  

^a BURNHAM INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ceramide; membrane lipids; plasmalogen; pre clinical Alzheimer's disease; shotgun lipidomics; sulfatide

Indexed keywords

CERAMIDE; MEMBRANE LIPID; PHOSPHATIDYLETHANOLAMINE; SULFATIDE;

ADULT; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID ANALYSIS; LIPIDOMICS; MALE; MEMBRANE DAMAGE; MIDDLE AGED; NEUROPATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL;

EID: 84890115095     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12368     Document Type: Article

References (40)

1. Bozzali M., Falini A., Franceschi M., Cercignani M., Zuffi M., Scotti G., Comi G., and, Filippi M., (2002) White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry 72, 742-746.
2. Braak H., and, Braak E., (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259.
3. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., and, Del Tredici K., (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389-404.
4. Cairns N. J., Taylor-Reinwald L., and, Morris J. C., (2010) Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core. Alzheimers Dement. 6, 274-279.
5. Cheng H., Xu J., McKeel D. W. Jr, and, Han X., (2003) Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study. Cell. Mol. Biol. 49, 809-818.
6. Cheng H., Sun G., Yang K., Gross R. W., and, Han X., (2010a) Selective desorption/ionization of sulfatides by MALDI-MS facilitated using 9-aminoacridine as matrix. J. Lipid Res. 51, 1599-1609.
7. Cheng H., Zhou Y., Holtzman D. M., and, Han X., (2010b) Apolipoprotein E mediates sulfatide depletion in amyloid precursor protein transgenic animal models of Alzheimer's disease. Neurobiol. Aging 31, 1188-1196.
8. Fagan A. M., Mintun M. A., Mach R. H., et al,. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59, 512-519.
9. Goodenowe D. B., Cook L. L., Liu J., et al,. (2007) Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 48, 2485-2498.
10. Han X., (2005) Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2, 65-77.
11. Han X,. (2007) Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stages of Alzheimer's disease: a tale of shotgun lipidomics. J. Neurochem. 103 (s1), 171-179.
12. Han X., (2010) The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease. Mol. Neurobiol. 41, 97-106.
13. Han X., Holtzman D. M., and, McKeel D. W. Jr, (2001) Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77, 1168-1180.
14. Han X., Holtzman D. M., McKeel D. W. Jr, Kelley J., and, Morris J. C., (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 82, 809-818.
15. Han X., Cheng H., Fryer J. D., Fagan A. M., and, Holtzman D. M., (2003a) Novel role for apolipoprotein E in the central nervous system: Modulation of sulfatide content. J. Biol. Chem. 278, 8043-8051.
16. Han X., Fagan A. M., Cheng H., Morris J. C., Xiong C., and, Holtzman D. M., (2003b) Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann. Neurol. 54, 115-119.
17. Han X., Rozen S., Boyle S., Hellegers C., Cheng H., Burke J. R., Welsh-Bohmer K. A., Doraiswamy P. M., and, Kaddurah-Daouk R., (2011) Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 6, e21643.
18. Han X., Yang K., and, Gross R. W., (2012) Multi-dimensional mass spectrometry-based shotgun lipidomics and novel strategies for lipidomic analyses. Mass Spectrom. Rev. 31, 134-178.
19. Holtzman D. M., Herz J., and, Bu G., (2012) Apolipoprotein e and apolipoprotein e receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006312.
20. Jiang X., Cheng H., Yang K., Gross R. W., and, Han X., (2007) Alkaline methanolysis of lipid extracts extends shotgun lipidomics analyses to the low abundance regime of cellular sphingolipids. Anal. Biochem. 371, 135-145.
21. Jones L., Harold D., and, Williams J., (2010) Genetic evidence for the involvement of lipid metabolism in Alzheimer's disease. Biochim. Biophys. Acta 1801, 754-761.
22. Kiebish M. A., Young D. M., Lehman J. J., and, Han X., (2012) Chronic caloric restriction attenuates a loss of sulfatide content in the PGC-1α-/- mouse cortex: a potential lipidomic role of PGC-1α in neurodegeneration. J. Lipid Res. 53, 273-281.
23. Mangialasche F., Solomon A., Winblad B., Mecocci P., and, Kivipelto M., (2010) Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9, 702-716.
24. Marcus J., Honigbaum S., Shroff S., Honke K., Rosenbluth J., and, Dupree J. L., (2006) Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia 53, 372-381.
25. Medina D., DeToledo-Morrell L., Urresta F., Gabrieli J. D., Moseley M., Fleischman D., Bennett D. A., Leurgans S., Turner D. A., and, Stebbins G. T., (2006) White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study. Neurobiol. Aging 27, 663-672.
26. Mirra S. S., Heyman A., McKeel D., Sumi S. M., Crain B. J., Brownlee L. M., Vogel F. S., Hughes J. P., van Belle G., and, Berg L., (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
27. Montine T. J., Phelps C. H., Beach T. G., et al,. (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 123, 1-11.
28. Morris J. C., (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412-2414.
29. NIA-Reagan Institute. (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging 18 (suppl), S1-S2.
30. Price J. L., McKeel D. W. Jr, Buckles V. D., et al,. (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 30, 1026-1036.
31. Rothhaar T. L., Grosgen S., Haupenthal V. J., Burg V. K., Hundsdorfer B., Mett J., Riemenschneider M., Grimm H. S., Hartmann T., and, Grimm M. O., (2012) Plasmalogens inhibit APP processing by directly affecting gamma-secretase activity in Alzheimer's disease. ScientificWorldJournal 2012, 141240.
32. Salomone S., Caraci F., Leggio G. M., Fedotova J., and, Drago F., (2012) New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br. J. Clin. Pharmacol. 73, 504-517.
33. Takahashi T., and, Suzuki T., (2012) Role of sulfatide in normal and pathological cells and tissues. J. Lipid Res. 53, 1437-1450.
34. Waldemar G., Dubois B., Emre M., Georges J., McKeith I. G., Rossor M., Scheltens P., Tariska P., and, Winblad B., (2007) Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur. J. Neurol. 14, e1-e26.
35. Xie S., Xiao J. X., Gong G. L., Zang Y. F., Wang Y. H., Wu H. K., and, Jiang X. X., (2006) Voxel-based detection of white matter abnormalities in mild Alzheimer disease. Neurology 66, 1845-1849.
36. Yang K., and, Han X., (2011) Accurate quantification of lipid species by electrospray ionization mass spectrometry-meets a key challenge in lipidomics. Metabolites 1, 21-40.
37. Yang K., Zhao Z., Gross R. W., and, Han X., (2007) Shotgun lipidomics identifies a paired rule for the presence of isomeric ether phospholipid molecular species. PLoS ONE 2, e1368.
38. Yang K., Cheng H., Gross R. W., and, Han X., (2009) Automated lipid identification and quantification by multi-dimensional mass spectrometry-based shotgun lipidomics. Anal. Chem. 81, 4356-4368.
39. Yoshiura T., Mihara F., Koga H., et al,. (2006) Mapping of subcortical white matter abnormality in Alzheimer's disease using diffusion-weighted magnetic resonance imaging. Acad. Radiol. 13, 1460-1464.
40. Zhang Y., Schuff N., Du A. T., Rosen H. J., Kramer J. H., Gorno-Tempini M. L., Miller B. L., and, Weiner M. W., (2009) White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI. Brain 132, 2579-2592.